MovDisordV3, PascalFrancis, Corpus, bibRecord, 000339

Long-Term Outcome of 32 Patients With Chorea and Systemic Lupus Erythematosus or Antiphospholipid Antibodies

Identifieur interne : 000339 ( PascalFrancis/Corpus ); précédent : 000338; suivant : 000340

Long-Term Outcome of 32 Patients With Chorea and Systemic Lupus Erythematosus or Antiphospholipid Antibodies

Auteurs : Peggy Reiner ; Damien Galanaud ; Gaëlle Leroux ; Marie Vidailhet ; Julien Haroche ; Du Le Thi Huong ; Camille Frances ; Thomas Papo ; Christian De Gennes ; Lucile Musset ; Bertrand Wechsler ; Zahir Amoura ; Jean-Charles Piette ; Nathalie Costedoat-Chalumeau

Source :

Movement disorders [ 0885-3185 ] ; 2011.

RBID : Pascal:12-0026980

Descripteurs français

Pascal (Inist)
- Syndrome choréique, Lupus érythémateux disséminé, Syndrome des antiphospholipides, Thrombose, Pathologie du système nerveux, Long terme, Pronostic, Homme, Thrombocyte.

English descriptors

KwdEn :
- Antiphospholipid antibody syndrome, Chorea, Human, Long term, Nervous system diseases, Platelet, Prognosis, Systemic lupus erythematosus, Thrombosis.

Abstract

Objective: The aim of this work was to describe chorea during systemic lupus erythematosus or antiphospholipid antibodies and its long-term outcome. Methods: We retrospectively analyzed clinical features, laboratory findings, imaging characteristics, and outcome in a series of 32 patients. Results: Most patients were women (28 of 32), and mean age at onset of chorea was 20.6 (9-62) years. Chorea was inaugural for 28 patients. Improvement was observed with various treatments. During follow-up (12.2 ±11.3 years), severe manifestations of systemic lupus erythematosus were rare. Antiphospholipid antibodies were repeatedly positive for 90% of the patients. Twelve patients developed arterial thrombosis. Prophylactic treatment with antithrombotic therapy might reduce the risk of further thrombosis (8% versus 57%; P = 0.01). Cardiac valvulopathy occurred in 22 patients during follow-up. Chorea relapsed in 8 cases. Conclusions: Chorea had a good outcome in itself. This long-term follow-up shows, for the first time, that these patients have substantial risk for further arterial thrombosis.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 26`
A06				`@2 13`
A08	`01`	`1`	`ENG`	`@1 Long-Term Outcome of 32 Patients With Chorea and Systemic Lupus Erythematosus or Antiphospholipid Antibodies`
A11	`01`	`1`		`@1 REINER (Peggy)`
A11	`02`	`1`		`@1 GALANAUD (Damien)`
A11	`03`	`1`		`@1 LEROUX (Gaëlle)`
A11	`04`	`1`		`@1 VIDAILHET (Marie)`
A11	`05`	`1`		`@1 HAROCHE (Julien)`
A11	`06`	`1`		`@1 THI HUONG (Du Le)`
A11	`07`	`1`		`@1 FRANCES (Camille)`
A11	`08`	`1`		`@1 PAPO (Thomas)`
A11	`09`	`1`		`@1 DE GENNES (Christian)`
A11	`10`	`1`		`@1 MUSSET (Lucile)`
A11	`11`	`1`		`@1 WECHSLER (Bertrand)`
A11	`12`	`1`		`@1 AMOURA (Zahir)`
A11	`13`	`1`		`@1 PIETTE (Jean-Charles)`
A11	`14`	`1`		`@1 COSTEDOAT-CHALUMEAU (Nathalie)`
A14	`01`			`@1 Service de Neurologie, AP-HP, Hôpital Lariboisière @2 Paris @3 FRA @Z 1 aut.`
A14	`02`			`@1 Service de Médecine Interne, Centre de Reference National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière @2 Paris @3 FRA @Z 3 aut. @Z 5 aut. @Z 6 aut. @Z 9 aut. @Z 11 aut. @Z 12 aut. @Z 13 aut. @Z 14 aut.`
A14	`03`			`@1 Service de Neuroradiologie, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière @2 Paris @3 FRA @Z 2 aut.`
A14	`04`			`@1 Fédération des Maladies du Système Nerveux Central, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière @2 Paris @3 FRA @Z 4 aut.`
A14	`05`			`@1 Service de Dermatologie, Hôpital Tenon, AP-HP @2 Paris @3 FRA @Z 7 aut.`
A14	`06`			`@1 Service de Médecine Interne, AP-HP, Hôpital Bichat @2 Paris @3 FRA @Z 8 aut.`
A14	`07`			`@1 Service d'Immunochimie, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière @2 Paris @3 FRA @Z 10 aut.`
A20				`@1 2422-2427`
A21				`@1 2011`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000505925010190`
A44				`@0 0000 @1 © 2012 INIST-CNRS. All rights reserved.`
A45				`@0 26 ref.`
A47	`01`	`1`		`@0 12-0026980`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Objective: The aim of this work was to describe chorea during systemic lupus erythematosus or antiphospholipid antibodies and its long-term outcome. Methods: We retrospectively analyzed clinical features, laboratory findings, imaging characteristics, and outcome in a series of 32 patients. Results: Most patients were women (28 of 32), and mean age at onset of chorea was 20.6 (9-62) years. Chorea was inaugural for 28 patients. Improvement was observed with various treatments. During follow-up (12.2 ±11.3 years), severe manifestations of systemic lupus erythematosus were rare. Antiphospholipid antibodies were repeatedly positive for 90% of the patients. Twelve patients developed arterial thrombosis. Prophylactic treatment with antithrombotic therapy might reduce the risk of further thrombosis (8% versus 57%; P = 0.01). Cardiac valvulopathy occurred in 22 patients during follow-up. Chorea relapsed in 8 cases. Conclusions: Chorea had a good outcome in itself. This long-term follow-up shows, for the first time, that these patients have substantial risk for further arterial thrombosis.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17F`
C03	`01`	`X`	`FRE`	`@0 Syndrome choréique @5 01`
C03	`01`	`X`	`ENG`	`@0 Chorea @5 01`
C03	`01`	`X`	`SPA`	`@0 Corea síndrome @5 01`
C03	`02`	`X`	`FRE`	`@0 Lupus érythémateux disséminé @2 NM @5 02`
C03	`02`	`X`	`ENG`	`@0 Systemic lupus erythematosus @2 NM @5 02`
C03	`02`	`X`	`SPA`	`@0 Lupus eritematoso sistémico @2 NM @5 02`
C03	`03`	`X`	`FRE`	`@0 Syndrome des antiphospholipides @5 03`
C03	`03`	`X`	`ENG`	`@0 Antiphospholipid antibody syndrome @5 03`
C03	`03`	`X`	`SPA`	`@0 Antifosfolípido síndrome @5 03`
C03	`04`	`X`	`FRE`	`@0 Thrombose @5 04`
C03	`04`	`X`	`ENG`	`@0 Thrombosis @5 04`
C03	`04`	`X`	`SPA`	`@0 Trombosis @5 04`
C03	`05`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 05`
C03	`05`	`X`	`ENG`	`@0 Nervous system diseases @5 05`
C03	`05`	`X`	`SPA`	`@0 Sistema nervioso patología @5 05`
C03	`06`	`X`	`FRE`	`@0 Long terme @5 09`
C03	`06`	`X`	`ENG`	`@0 Long term @5 09`
C03	`06`	`X`	`SPA`	`@0 Largo plazo @5 09`
C03	`07`	`X`	`FRE`	`@0 Pronostic @5 10`
C03	`07`	`X`	`ENG`	`@0 Prognosis @5 10`
C03	`07`	`X`	`SPA`	`@0 Pronóstico @5 10`
C03	`08`	`X`	`FRE`	`@0 Homme @5 11`
C03	`08`	`X`	`ENG`	`@0 Human @5 11`
C03	`08`	`X`	`SPA`	`@0 Hombre @5 11`
C03	`09`	`X`	`FRE`	`@0 Thrombocyte @5 78`
C03	`09`	`X`	`ENG`	`@0 Platelet @5 78`
C03	`09`	`X`	`SPA`	`@0 Trombocito @5 78`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Mouvement involontaire @5 39`
C07	`03`	`X`	`ENG`	`@0 Involuntary movement @5 39`
C07	`03`	`X`	`SPA`	`@0 Movimiento involuntario @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
C07	`05`	`X`	`FRE`	`@0 Trouble neurologique @5 42`
C07	`05`	`X`	`ENG`	`@0 Neurological disorder @5 42`
C07	`05`	`X`	`SPA`	`@0 Trastorno neurológico @5 42`
C07	`06`	`X`	`FRE`	`@0 Maladie autoimmune @5 43`
C07	`06`	`X`	`ENG`	`@0 Autoimmune disease @5 43`
C07	`06`	`X`	`SPA`	`@0 Enfermedad autoinmune @5 43`
C07	`07`	`X`	`FRE`	`@0 Maladie de système @5 44`
C07	`07`	`X`	`ENG`	`@0 Systemic disease @5 44`
C07	`07`	`X`	`SPA`	`@0 Enfermedad sistémica @5 44`
C07	`08`	`X`	`FRE`	`@0 Pathologie de la peau @5 45`
C07	`08`	`X`	`ENG`	`@0 Skin disease @5 45`
C07	`08`	`X`	`SPA`	`@0 Piel patología @5 45`
C07	`09`	`X`	`FRE`	`@0 Pathologie du tissu conjonctif @5 46`
C07	`09`	`X`	`ENG`	`@0 Connective tissue disease @5 46`
C07	`09`	`X`	`SPA`	`@0 Tejido conjuntivo patología @5 46`
C07	`10`	`X`	`FRE`	`@0 Immunopathologie @5 47`
C07	`10`	`X`	`ENG`	`@0 Immunopathology @5 47`
C07	`10`	`X`	`SPA`	`@0 Inmunopatología @5 47`
C07	`11`	`X`	`FRE`	`@0 Pathologie de l'appareil circulatoire @5 48`
C07	`11`	`X`	`ENG`	`@0 Cardiovascular disease @5 48`
C07	`11`	`X`	`SPA`	`@0 Aparato circulatorio patología @5 48`
C07	`12`	`X`	`FRE`	`@0 Hémopathie @5 49`
C07	`12`	`X`	`ENG`	`@0 Hemopathy @5 49`
C07	`12`	`X`	`SPA`	`@0 Hemopatía @5 49`
C07	`13`	`X`	`FRE`	`@0 Pathologie des vaisseaux sanguins @5 50`
C07	`13`	`X`	`ENG`	`@0 Vascular disease @5 50`
C07	`13`	`X`	`SPA`	`@0 Vaso sanguíneo patología @5 50`
N21				`@1 009`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 12-0026980 INIST
ET :	Long-Term Outcome of 32 Patients With Chorea and Systemic Lupus Erythematosus or Antiphospholipid Antibodies
AU :	REINER (Peggy); GALANAUD (Damien); LEROUX (Gaëlle); VIDAILHET (Marie); HAROCHE (Julien); THI HUONG (Du Le); FRANCES (Camille); PAPO (Thomas); DE GENNES (Christian); MUSSET (Lucile); WECHSLER (Bertrand); AMOURA (Zahir); PIETTE (Jean-Charles); COSTEDOAT-CHALUMEAU (Nathalie)
AF :	Service de Neurologie, AP-HP, Hôpital Lariboisière/Paris/France (1 aut.); Service de Médecine Interne, Centre de Reference National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière/Paris/France (3 aut., 5 aut., 6 aut., 9 aut., 11 aut., 12 aut., 13 aut., 14 aut.); Service de Neuroradiologie, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière/Paris/France (2 aut.); Fédération des Maladies du Système Nerveux Central, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière/Paris/France (4 aut.); Service de Dermatologie, Hôpital Tenon, AP-HP/Paris/France (7 aut.); Service de Médecine Interne, AP-HP, Hôpital Bichat/Paris/France (8 aut.); Service d'Immunochimie, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière/Paris/France (10 aut.)
DT :	Publication en série; Courte communication, note brève; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2011; Vol. 26; No. 13; Pp. 2422-2427; Bibl. 26 ref.
LA :	Anglais
EA :	Objective: The aim of this work was to describe chorea during systemic lupus erythematosus or antiphospholipid antibodies and its long-term outcome. Methods: We retrospectively analyzed clinical features, laboratory findings, imaging characteristics, and outcome in a series of 32 patients. Results: Most patients were women (28 of 32), and mean age at onset of chorea was 20.6 (9-62) years. Chorea was inaugural for 28 patients. Improvement was observed with various treatments. During follow-up (12.2 ±11.3 years), severe manifestations of systemic lupus erythematosus were rare. Antiphospholipid antibodies were repeatedly positive for 90% of the patients. Twelve patients developed arterial thrombosis. Prophylactic treatment with antithrombotic therapy might reduce the risk of further thrombosis (8% versus 57%; P = 0.01). Cardiac valvulopathy occurred in 22 patients during follow-up. Chorea relapsed in 8 cases. Conclusions: Chorea had a good outcome in itself. This long-term follow-up shows, for the first time, that these patients have substantial risk for further arterial thrombosis.
CC :	002B17; 002B17F
FD :	Syndrome choréique; Lupus érythémateux disséminé; Syndrome des antiphospholipides; Thrombose; Pathologie du système nerveux; Long terme; Pronostic; Homme; Thrombocyte
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Mouvement involontaire; Pathologie du système nerveux central; Trouble neurologique; Maladie autoimmune; Maladie de système; Pathologie de la peau; Pathologie du tissu conjonctif; Immunopathologie; Pathologie de l'appareil circulatoire; Hémopathie; Pathologie des vaisseaux sanguins
ED :	Chorea; Systemic lupus erythematosus; Antiphospholipid antibody syndrome; Thrombosis; Nervous system diseases; Long term; Prognosis; Human; Platelet
EG :	Cerebral disorder; Extrapyramidal syndrome; Involuntary movement; Central nervous system disease; Neurological disorder; Autoimmune disease; Systemic disease; Skin disease; Connective tissue disease; Immunopathology; Cardiovascular disease; Hemopathy; Vascular disease
SD :	Corea síndrome; Lupus eritematoso sistémico; Antifosfolípido síndrome; Trombosis; Sistema nervioso patología; Largo plazo; Pronóstico; Hombre; Trombocito
LO :	INIST-20953.354000505925010190
ID :	12-0026980

Links to Exploration step

Pascal:12-0026980

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Long-Term Outcome of 32 Patients With Chorea and Systemic Lupus Erythematosus or Antiphospholipid Antibodies</title>
<author><name sortKey="Reiner, Peggy" sort="Reiner, Peggy" uniqKey="Reiner P" first="Peggy" last="Reiner">Peggy Reiner</name>
<affiliation><inist:fA14 i1="01"><s1>Service de Neurologie, AP-HP, Hôpital Lariboisière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Galanaud, Damien" sort="Galanaud, Damien" uniqKey="Galanaud D" first="Damien" last="Galanaud">Damien Galanaud</name>
<affiliation><inist:fA14 i1="03"><s1>Service de Neuroradiologie, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Leroux, Gaelle" sort="Leroux, Gaelle" uniqKey="Leroux G" first="Gaëlle" last="Leroux">Gaëlle Leroux</name>
<affiliation><inist:fA14 i1="02"><s1>Service de Médecine Interne, Centre de Reference National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Vidailhet, Marie" sort="Vidailhet, Marie" uniqKey="Vidailhet M" first="Marie" last="Vidailhet">Marie Vidailhet</name>
<affiliation><inist:fA14 i1="04"><s1>Fédération des Maladies du Système Nerveux Central, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Haroche, Julien" sort="Haroche, Julien" uniqKey="Haroche J" first="Julien" last="Haroche">Julien Haroche</name>
<affiliation><inist:fA14 i1="02"><s1>Service de Médecine Interne, Centre de Reference National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Thi Huong, Du Le" sort="Thi Huong, Du Le" uniqKey="Thi Huong D" first="Du Le" last="Thi Huong">Du Le Thi Huong</name>
<affiliation><inist:fA14 i1="02"><s1>Service de Médecine Interne, Centre de Reference National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Frances, Camille" sort="Frances, Camille" uniqKey="Frances C" first="Camille" last="Frances">Camille Frances</name>
<affiliation><inist:fA14 i1="05"><s1>Service de Dermatologie, Hôpital Tenon, AP-HP</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Papo, Thomas" sort="Papo, Thomas" uniqKey="Papo T" first="Thomas" last="Papo">Thomas Papo</name>
<affiliation><inist:fA14 i1="06"><s1>Service de Médecine Interne, AP-HP, Hôpital Bichat</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="De Gennes, Christian" sort="De Gennes, Christian" uniqKey="De Gennes C" first="Christian" last="De Gennes">Christian De Gennes</name>
<affiliation><inist:fA14 i1="02"><s1>Service de Médecine Interne, Centre de Reference National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Musset, Lucile" sort="Musset, Lucile" uniqKey="Musset L" first="Lucile" last="Musset">Lucile Musset</name>
<affiliation><inist:fA14 i1="07"><s1>Service d'Immunochimie, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wechsler, Bertrand" sort="Wechsler, Bertrand" uniqKey="Wechsler B" first="Bertrand" last="Wechsler">Bertrand Wechsler</name>
<affiliation><inist:fA14 i1="02"><s1>Service de Médecine Interne, Centre de Reference National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Amoura, Zahir" sort="Amoura, Zahir" uniqKey="Amoura Z" first="Zahir" last="Amoura">Zahir Amoura</name>
<affiliation><inist:fA14 i1="02"><s1>Service de Médecine Interne, Centre de Reference National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Piette, Jean Charles" sort="Piette, Jean Charles" uniqKey="Piette J" first="Jean-Charles" last="Piette">Jean-Charles Piette</name>
<affiliation><inist:fA14 i1="02"><s1>Service de Médecine Interne, Centre de Reference National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Costedoat Chalumeau, Nathalie" sort="Costedoat Chalumeau, Nathalie" uniqKey="Costedoat Chalumeau N" first="Nathalie" last="Costedoat-Chalumeau">Nathalie Costedoat-Chalumeau</name>
<affiliation><inist:fA14 i1="02"><s1>Service de Médecine Interne, Centre de Reference National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0026980</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 12-0026980 INIST</idno>
<idno type="RBID">Pascal:12-0026980</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000339</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Long-Term Outcome of 32 Patients With Chorea and Systemic Lupus Erythematosus or Antiphospholipid Antibodies</title>
<author><name sortKey="Reiner, Peggy" sort="Reiner, Peggy" uniqKey="Reiner P" first="Peggy" last="Reiner">Peggy Reiner</name>
<affiliation><inist:fA14 i1="01"><s1>Service de Neurologie, AP-HP, Hôpital Lariboisière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Galanaud, Damien" sort="Galanaud, Damien" uniqKey="Galanaud D" first="Damien" last="Galanaud">Damien Galanaud</name>
<affiliation><inist:fA14 i1="03"><s1>Service de Neuroradiologie, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Leroux, Gaelle" sort="Leroux, Gaelle" uniqKey="Leroux G" first="Gaëlle" last="Leroux">Gaëlle Leroux</name>
<affiliation><inist:fA14 i1="02"><s1>Service de Médecine Interne, Centre de Reference National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Vidailhet, Marie" sort="Vidailhet, Marie" uniqKey="Vidailhet M" first="Marie" last="Vidailhet">Marie Vidailhet</name>
<affiliation><inist:fA14 i1="04"><s1>Fédération des Maladies du Système Nerveux Central, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Haroche, Julien" sort="Haroche, Julien" uniqKey="Haroche J" first="Julien" last="Haroche">Julien Haroche</name>
<affiliation><inist:fA14 i1="02"><s1>Service de Médecine Interne, Centre de Reference National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Thi Huong, Du Le" sort="Thi Huong, Du Le" uniqKey="Thi Huong D" first="Du Le" last="Thi Huong">Du Le Thi Huong</name>
<affiliation><inist:fA14 i1="02"><s1>Service de Médecine Interne, Centre de Reference National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Frances, Camille" sort="Frances, Camille" uniqKey="Frances C" first="Camille" last="Frances">Camille Frances</name>
<affiliation><inist:fA14 i1="05"><s1>Service de Dermatologie, Hôpital Tenon, AP-HP</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Papo, Thomas" sort="Papo, Thomas" uniqKey="Papo T" first="Thomas" last="Papo">Thomas Papo</name>
<affiliation><inist:fA14 i1="06"><s1>Service de Médecine Interne, AP-HP, Hôpital Bichat</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="De Gennes, Christian" sort="De Gennes, Christian" uniqKey="De Gennes C" first="Christian" last="De Gennes">Christian De Gennes</name>
<affiliation><inist:fA14 i1="02"><s1>Service de Médecine Interne, Centre de Reference National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Musset, Lucile" sort="Musset, Lucile" uniqKey="Musset L" first="Lucile" last="Musset">Lucile Musset</name>
<affiliation><inist:fA14 i1="07"><s1>Service d'Immunochimie, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wechsler, Bertrand" sort="Wechsler, Bertrand" uniqKey="Wechsler B" first="Bertrand" last="Wechsler">Bertrand Wechsler</name>
<affiliation><inist:fA14 i1="02"><s1>Service de Médecine Interne, Centre de Reference National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Amoura, Zahir" sort="Amoura, Zahir" uniqKey="Amoura Z" first="Zahir" last="Amoura">Zahir Amoura</name>
<affiliation><inist:fA14 i1="02"><s1>Service de Médecine Interne, Centre de Reference National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Piette, Jean Charles" sort="Piette, Jean Charles" uniqKey="Piette J" first="Jean-Charles" last="Piette">Jean-Charles Piette</name>
<affiliation><inist:fA14 i1="02"><s1>Service de Médecine Interne, Centre de Reference National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Costedoat Chalumeau, Nathalie" sort="Costedoat Chalumeau, Nathalie" uniqKey="Costedoat Chalumeau N" first="Nathalie" last="Costedoat-Chalumeau">Nathalie Costedoat-Chalumeau</name>
<affiliation><inist:fA14 i1="02"><s1>Service de Médecine Interne, Centre de Reference National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiphospholipid antibody syndrome</term>
<term>Chorea</term>
<term>Human</term>
<term>Long term</term>
<term>Nervous system diseases</term>
<term>Platelet</term>
<term>Prognosis</term>
<term>Systemic lupus erythematosus</term>
<term>Thrombosis</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Syndrome choréique</term>
<term>Lupus érythémateux disséminé</term>
<term>Syndrome des antiphospholipides</term>
<term>Thrombose</term>
<term>Pathologie du   système nerveux</term>
<term>Long terme</term>
<term>Pronostic</term>
<term>Homme</term>
<term>Thrombocyte</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objective: The aim of this work was to describe chorea during systemic lupus erythematosus or antiphospholipid antibodies and its long-term outcome. Methods: We retrospectively analyzed clinical features, laboratory findings, imaging characteristics, and outcome in a series of 32 patients. Results: Most patients were women (28 of 32), and mean age at onset of chorea was 20.6 (9-62) years. Chorea was inaugural for 28 patients. Improvement was observed with various treatments. During follow-up (12.2 ±11.3 years), severe manifestations of systemic lupus erythematosus were rare. Antiphospholipid antibodies were repeatedly positive for 90% of the patients. Twelve patients developed arterial thrombosis. Prophylactic treatment with antithrombotic therapy might reduce the risk of further thrombosis (8% versus 57%; P = 0.01). Cardiac valvulopathy occurred in 22 patients during follow-up. Chorea relapsed in 8 cases. Conclusions: Chorea had a good outcome in itself. This long-term follow-up shows, for the first time, that these patients have substantial risk for further arterial thrombosis.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>26</s2>
</fA05>
<fA06><s2>13</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Long-Term Outcome of 32 Patients With Chorea and Systemic Lupus Erythematosus or Antiphospholipid Antibodies</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>REINER (Peggy)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>GALANAUD (Damien)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>LEROUX (Gaëlle)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>VIDAILHET (Marie)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>HAROCHE (Julien)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>THI HUONG (Du Le)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>FRANCES (Camille)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>PAPO (Thomas)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>DE GENNES (Christian)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>MUSSET (Lucile)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>WECHSLER (Bertrand)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>AMOURA (Zahir)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>PIETTE (Jean-Charles)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>COSTEDOAT-CHALUMEAU (Nathalie)</s1>
</fA11>
<fA14 i1="01"><s1>Service de Neurologie, AP-HP, Hôpital Lariboisière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Service de Médecine Interne, Centre de Reference National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Service de Neuroradiologie, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Fédération des Maladies du Système Nerveux Central, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Service de Dermatologie, Hôpital Tenon, AP-HP</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Service de Médecine Interne, AP-HP, Hôpital Bichat</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Service d'Immunochimie, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA20><s1>2422-2427</s1>
</fA20>
<fA21><s1>2011</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000505925010190</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>26 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0026980</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Objective: The aim of this work was to describe chorea during systemic lupus erythematosus or antiphospholipid antibodies and its long-term outcome. Methods: We retrospectively analyzed clinical features, laboratory findings, imaging characteristics, and outcome in a series of 32 patients. Results: Most patients were women (28 of 32), and mean age at onset of chorea was 20.6 (9-62) years. Chorea was inaugural for 28 patients. Improvement was observed with various treatments. During follow-up (12.2 ±11.3 years), severe manifestations of systemic lupus erythematosus were rare. Antiphospholipid antibodies were repeatedly positive for 90% of the patients. Twelve patients developed arterial thrombosis. Prophylactic treatment with antithrombotic therapy might reduce the risk of further thrombosis (8% versus 57%; P = 0.01). Cardiac valvulopathy occurred in 22 patients during follow-up. Chorea relapsed in 8 cases. Conclusions: Chorea had a good outcome in itself. This long-term follow-up shows, for the first time, that these patients have substantial risk for further arterial thrombosis.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17F</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Syndrome choréique</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Chorea</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Corea síndrome</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Lupus érythémateux disséminé</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Systemic lupus erythematosus</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Lupus eritematoso sistémico</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Syndrome des antiphospholipides</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Antiphospholipid antibody syndrome</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Antifosfolípido síndrome</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Thrombose</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Thrombosis</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Trombosis</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Long terme</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Long term</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Largo plazo</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Pronostic</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Prognosis</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Pronóstico</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Homme</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Human</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Hombre</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Thrombocyte</s0>
<s5>78</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Platelet</s0>
<s5>78</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Trombocito</s0>
<s5>78</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Maladie autoimmune</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Autoimmune disease</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Enfermedad autoinmune</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Maladie de système</s0>
<s5>44</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Systemic disease</s0>
<s5>44</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Enfermedad sistémica</s0>
<s5>44</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Pathologie de la peau</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Skin disease</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Piel patología</s0>
<s5>45</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Pathologie du  tissu conjonctif</s0>
<s5>46</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Connective tissue disease</s0>
<s5>46</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Tejido conjuntivo patología</s0>
<s5>46</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Immunopathologie</s0>
<s5>47</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Immunopathology</s0>
<s5>47</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Inmunopatología</s0>
<s5>47</s5>
</fC07>
<fC07 i1="11" i2="X" l="FRE"><s0>Pathologie de l'appareil circulatoire</s0>
<s5>48</s5>
</fC07>
<fC07 i1="11" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
<s5>48</s5>
</fC07>
<fC07 i1="11" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
<s5>48</s5>
</fC07>
<fC07 i1="12" i2="X" l="FRE"><s0>Hémopathie</s0>
<s5>49</s5>
</fC07>
<fC07 i1="12" i2="X" l="ENG"><s0>Hemopathy</s0>
<s5>49</s5>
</fC07>
<fC07 i1="12" i2="X" l="SPA"><s0>Hemopatía</s0>
<s5>49</s5>
</fC07>
<fC07 i1="13" i2="X" l="FRE"><s0>Pathologie des vaisseaux sanguins</s0>
<s5>50</s5>
</fC07>
<fC07 i1="13" i2="X" l="ENG"><s0>Vascular disease</s0>
<s5>50</s5>
</fC07>
<fC07 i1="13" i2="X" l="SPA"><s0>Vaso sanguíneo patología</s0>
<s5>50</s5>
</fC07>
<fN21><s1>009</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 12-0026980 INIST</NO>
<ET>Long-Term Outcome of 32 Patients With Chorea and Systemic Lupus Erythematosus or Antiphospholipid Antibodies</ET>
<AU>REINER (Peggy); GALANAUD (Damien); LEROUX (Gaëlle); VIDAILHET (Marie); HAROCHE (Julien); THI HUONG (Du Le); FRANCES (Camille); PAPO (Thomas); DE GENNES (Christian); MUSSET (Lucile); WECHSLER (Bertrand); AMOURA (Zahir); PIETTE (Jean-Charles); COSTEDOAT-CHALUMEAU (Nathalie)</AU>
<AF>Service de Neurologie, AP-HP, Hôpital Lariboisière/Paris/France (1 aut.); Service de Médecine Interne, Centre de Reference National pour le Lupus Systémique et le Syndrome des Antiphospholipides, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière/Paris/France (3 aut., 5 aut., 6 aut., 9 aut., 11 aut., 12 aut., 13 aut., 14 aut.); Service de Neuroradiologie, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière/Paris/France (2 aut.); Fédération des Maladies du Système Nerveux Central, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière/Paris/France (4 aut.); Service de Dermatologie, Hôpital Tenon, AP-HP/Paris/France (7 aut.); Service de Médecine Interne, AP-HP, Hôpital Bichat/Paris/France (8 aut.); Service d'Immunochimie, AP-HP, Centre Hospitalier Universitaire Pitié-Salpêtrière/Paris/France (10 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2011; Vol. 26; No. 13; Pp. 2422-2427; Bibl. 26 ref.</SO>
<LA>Anglais</LA>
<EA>Objective: The aim of this work was to describe chorea during systemic lupus erythematosus or antiphospholipid antibodies and its long-term outcome. Methods: We retrospectively analyzed clinical features, laboratory findings, imaging characteristics, and outcome in a series of 32 patients. Results: Most patients were women (28 of 32), and mean age at onset of chorea was 20.6 (9-62) years. Chorea was inaugural for 28 patients. Improvement was observed with various treatments. During follow-up (12.2 ±11.3 years), severe manifestations of systemic lupus erythematosus were rare. Antiphospholipid antibodies were repeatedly positive for 90% of the patients. Twelve patients developed arterial thrombosis. Prophylactic treatment with antithrombotic therapy might reduce the risk of further thrombosis (8% versus 57%; P = 0.01). Cardiac valvulopathy occurred in 22 patients during follow-up. Chorea relapsed in 8 cases. Conclusions: Chorea had a good outcome in itself. This long-term follow-up shows, for the first time, that these patients have substantial risk for further arterial thrombosis.</EA>
<CC>002B17; 002B17F</CC>
<FD>Syndrome choréique; Lupus érythémateux disséminé; Syndrome des antiphospholipides; Thrombose; Pathologie du   système nerveux; Long terme; Pronostic; Homme; Thrombocyte</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Mouvement involontaire; Pathologie du   système nerveux central; Trouble neurologique; Maladie autoimmune; Maladie de système; Pathologie de la peau; Pathologie du  tissu conjonctif; Immunopathologie; Pathologie de l'appareil circulatoire; Hémopathie; Pathologie des vaisseaux sanguins</FG>
<ED>Chorea; Systemic lupus erythematosus; Antiphospholipid antibody syndrome; Thrombosis; Nervous system diseases; Long term; Prognosis; Human; Platelet</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Involuntary movement; Central nervous system disease; Neurological disorder; Autoimmune disease; Systemic disease; Skin disease; Connective tissue disease; Immunopathology; Cardiovascular disease; Hemopathy; Vascular disease</EG>
<SD>Corea síndrome; Lupus eritematoso sistémico; Antifosfolípido síndrome; Trombosis; Sistema nervioso patología; Largo plazo; Pronóstico; Hombre; Trombocito</SD>
<LO>INIST-20953.354000505925010190</LO>
<ID>12-0026980</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000339 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000339 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:12-0026980
   |texte=   Long-Term Outcome of 32 Patients With Chorea and Systemic Lupus Erythematosus or Antiphospholipid Antibodies
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Long-Term Outcome of 32 Patients With Chorea and Systemic Lupus Erythematosus or Antiphospholipid Antibodies

Long-Term Outcome of 32 Patients With Chorea and Systemic Lupus Erythematosus or Antiphospholipid Antibodies

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri